Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course
(firmenpresse) - NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM -- (Marketwired) -- 09/22/16 -- Avita Medical Ltd (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today it will host a ReCell® Symposium at the EBA Educational Course, taking place in Birmingham, UK, 26-27 September.
The Symposium '' will support the education and adoption of new technologies and share the experiences of lead clinicians who have used ReCell® for burns. The Symposium is taking place at 9.10 a.m. during . Speakers taking part in the Symposium are:
- Plastic Surgeon, Chelsea and Westminster Hospital London
- Plastic and Aesthetic Surgeon, Malteser Hospital, Bonn
- Plastic, Reconstructive, Hand, Aesthetic and Burn Surgeon - Klinikum Bogenhausen, Munich
- Plastic and Aesthetic Surgeon, Unfallkrankenhaus, Berlin
- University of Huddersfield
The EBA Educational Course is a bi-annual event which sees 300 delegates, including plastic surgeons, anesthesiologists, nurse specialists and burn team members from Europe and beyond. This year''s theme is Burns at the Extremes of Age, incorporating acute care and resuscitation, infection and sepsis, skin substitutes; present and future and psychological aspects of burns.
To meet the Avita team, visit Stand 8 in the exhibition hall.
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita''s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient''s own skin. The Company''s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit .
ReCell® is a medical device which enables clinicians to safely and rapidly create a treatment solution for burns and acute injuries from a patient''s own skin.
Using a small sample of skin, the device enables the production of a Regenerative Epithelial Suspension (RES™). The autologous suspension contains the multi-phenotype cells and wound-healing factors essential for natural healthy skin regeneration and healing. The procedure performed at the patient''s bedside takes about 30 minutes from collecting the biopsy to spraying of the suspension onto the affected area.
ReCell® can be used in conjunction with conventional treatments for burns and reconstructive procedures, and has been used safely in thousands of treatments worldwide. Recent data showed that treatment of ReCell® decreased length of hospital stay in patients with large burns by 47%.
For more information, visit:
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
Gemma Howe/Sue Charles
Phone +44 (0)20 7866 7860
Dean Felton
Phone: +61 3 9620 3333
Mobile: +61 (0) 411 698 499
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2016 - 18:28 Uhr
Sprache: Deutsch
News-ID 1459857
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM
Phone:
Kategorie:
Medical Devices
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 381 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
